PT  - JOURNAL ARTICLE
AU  - Bäuerl, Christine
AU  - Randazzo, Walter
AU  - Sánchez, Gloria
AU  - Selma-Royo, Marta
AU  - Garcia-Verdevio, Elia
AU  - Martínez-Rodríguez, Laura
AU  - Parra-Llorca, Anna
AU  - Lerin, Carles
AU  - Fumadó, Victoria
AU  - Crovetto, Francesca
AU  - Crispi, Fátima
AU  - Pérez-Cano, Francisco J
AU  - Rodríguez, Gerardo
AU  - Ruíz-Redondo, Gema
AU  - Campoy, Cristina
AU  - Martínez-Costa, Cecilia
AU  - Collado, Maria Carmen
AU  - ,
TI  - SARS-CoV-2 RNA and antibody detection in human milk from a prospective multicenter study in Spain
AID  - 10.1101/2021.05.06.21256766
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.06.21256766
4099  - http://medrxiv.org/content/early/2021/05/13/2021.05.06.21256766.short
4100  - http://medrxiv.org/content/early/2021/05/13/2021.05.06.21256766.full
AB  - Background During the COVID-19 pandemic in 2020, breastfeeding in women positive for SARS-CoV-2 was compromised due to contradictory data regarding potential viral transmission. However, growing evidence confirms the relevant role of breast milk in providing passive immunity by generating and transmitting specific antibodies against the virus. Thus, our study aimed to develop and validate a specific protocol to detect SARS-CoV-2 in breast milk matrix as well as to determine the impact of maternal SARS-CoV-2 infection on presence, concentration, and persistence of specific SARS-CoV-2 antibodies.Study design/Methods A prospective multicenter longitudinal study in Spain was carried out from April to December 2020. A total of 60 mothers with SARS-CoV-2 infection and/or recovered from COVID-19 were included (n=52 PCR-diagnosed and n=8 seropositive). Data from maternal-infant clinical records and symptomatology were collected. A specific protocol was validated to detect SARS-CoV-2 RNA in breast milk, targeting the N1 region of the nucleocapsid gene and the envelope (E) gene. Presence and levels of SARS-CoV-2 specific immunoglobulins (Igs) -IgA, IgG, and IgM-in breast milk samples from COVID-19 patients and from 13 women before the pandemic were also evaluated.Results All breast milk samples showed negative results for SARS-CoV-2 RNA presence. We observed high intra- and inter-individual variability in the antibody response to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein for each of the three isotypes IgA, IgM and IgG. Protease domain (MPro) antibodies were also detected in milk. In general, 82.9 % of the milk samples were positive for at least one of the three antibody isotypes, being 52.86 % of those positive for all three Igs. Positivity rate for IgA was relatively stable over time (65.2 – 87.5 %), whereas it raised continuously for IgG (47.8 % the first ten days to 87.5 % from day 41 up to day 206 post-PCR confirmation).Conclusions Considering the lack of evidence for SARS-CoV-2 transmission through breast milk, our study confirms the safety of breastfeeding practices and highlights the relevance of virus-specific SARS-CoV-2 antibody transfer, that would provide passive immunity to breastfed infants and protect them against COVID-19 disease. This study provides crucial data to support official breastfeeding recommendations based on scientific evidence.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04768244Funding Statement-Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee of the Hospital Clinico Universitario of Valencia (Ref. 2020/133). A control group of women not exposed to SARS-CoV-2 and from prepandemic time was included from the MAMI birth cohort in Spain [15] (ClinicalTrials.gov Identifier: NCT03552939). This protocol was approved by the Ethical Committee of the Hospital Clinico Universitario of Valencia (Ref. 2015/0024) and by the local Ethical Committee of Atencion Primaria-Generalitat Valenciana (CEIC-APCV). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are available upon request